Hyporesponsiveness or resistance to the action of parathyroid hormone in chronic kidney disease

Abstract

Secondary hyperparathyroidism (SHPT) is an integral component of the chronic kidney disease-mineral and bone disorder (CKD-MBD). Many factors have been associated with the development and progression of SHPT but the presence of skeletal or calcemic resistance to the action of PTH in CKD has often gone unnoticed. The term hyporesponsiveness to PTH is currently preferred and, in this chapter, we will not only review the scientific timeline but also some of the molecular mechanisms behind. Moreover, the presence of resistance to the biological action of PTH is not unique in CKD since resistance to other hormones has also been described ("uremia as a receptor disease"). This hyporesponsiveness carries out important clinical implications since it explains, at least partially, not only the progressive nature of the pathogenesis of CKD-related PTH hypersecretion and parathyroid hyperplasia but also the increasing prevalence of adynamic bone disease in the CKD population. Therefore, we underline the importance of PTH control in all CKD stages, but not aiming to completely normalize PTH levels since a certain degree of SHPT may represent an adaptive clinical response. Future studies at the molecular level, i.e. on uremia or the recent description of the calcium-sensing receptor as a phosphate sensor, may become of great value beyond their significance to explain just the hyporesponsiveness to PTH in CKD.

Keywords: Calcaemic response; Calcio; Calcium; Chronic kidney disease-mineral and bone disorder; Fosfato; Hiperparatiroidismo secundario; Hormona paratiroidea; Metabolismo mineral; Parathyroid hormone; Parathyroid hormone receptor; Parathyroid hormone resistance; Phosphate; Receptor de la hormona paratiroidea; Resistencia a la hormona paratiroidea; Respuesta calcémica; Secondary hyperparathyroidism.